Details of the Drug Combinations

General Information of This Drug (ID: DMBK9AM)

Drug Name

PLX-4720 DMBK9AM

Synonyms

PLX 4720; PLX4720 (BRAF inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous melanoma	2C30	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PLX-4720 + Panobinostat	DCD16ZS	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
PLX-4720 + Idarubicin	DCRTJTG	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
PLX-4720 + Ibrutinib	DCLZP62	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
------------------------------------------------------------------------------------

References

1	Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist. 2011;16(3):296-309.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.